// App-Quantinova.ai

P1061 : INDIRECT TREATMENT COMPARISONS OF FEDRATINIB VERSUS NAVITOCLAX PLUS RUXOLITINIB: EFFECT ON SPLEEN VOLUME AND SYMPTOMS IN RUXOLITINIB-EXPOSED MYELOFIBROSIS PATIENTS

Researchers

Presenter

  • Pranav Abraham

Principal Investigators

  • Xiaomeng Liao

  • Manoj Chevli

  • Sarah Smith

Medical Centers

  • Bristol Myers Squibbs,Princeton,Vereinigte Staaten

  • Celgene, a Bristol-Myers Squibb Company,Uxbridge,Vereinigtes Königreich

  • Celgene, a Bristol-Myers Squibb Company,Uxbridge,United Kingdom

  • BresMed Health Solutions,Sheffield ,Royaume-uni

  • Celgene, a Bristol-Myers Squibb Company,Uxbridge,Reino Unido

  • Celgene, a Bristol-Myers Squibb Company,Uxbridge,Reino Unido

  • BresMed Health Soluti

  • Celgene, a Bristol-Myers Squibb Company,Uxbridge,Vereinigtes Königreich

  • Celgene, a B

  • Bristol Myers Squibb,Princeton,USA

  • BresMed Health Solutions Ltd,Sheffield,Verenigd Koninkrijk

  • Bristol Myers Squibb,Princeton, NJ,Estados Unidos

  • Bristol Myers Squibbs,Princeton,Vereinigte Staaten

  • Bristol Meyers Squibb,Princeton,United States

  • BresMed Health Solutions, Sheffield, United Kingdom

  • BresMed Health Solutions Ltd,Sheffield,Regno Unito

  • Celgene, a Bristol-Myers Squibb Company,Uxbridge,Reino Unido

  • Bristol Myers Squibb,Summit, NJ,Stati Uniti

  • Bristol Myers Squibb,Princeton, NJ,Estados Unidos

  • BresMed Health Solutions Ltd,Sheffield,Verenigd Koninkrijk

  • BresMed Health Solutions Ltd,Sheffield,Regno Unito

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Myelofibrosis

Biomarkers

  • Sustained virological response

Drug/Treatment

  • Ruxolitinib phosphate

  • Fedratinib

  • Navitoclax

Outcome

  • N/A

Study Design

  • Multinational

  • Cohort

Phase

  • N/A

Study Id's

  • NCT01523171

  • NCT03222609

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved